• 34211 Citations
  • 69 h-Index
19972019
If you made any changes in Pure these will be visible here soon.

Research Output 1997 2019

Filter
Article
2019

Accumulation of Circulating CCR7+ Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic Pathway

Cristiani, C. M., Turdo, A., Ventura, V., Apuzzo, T., Capone, M., Madonna, G., Mallardo, D., Garofalo, C., Giovannone, E. D., Grimaldi, A. M., Tallerico, R., Marcenaro, E., Pesce, S., Zotto, G. D., Agosti, V., Costanzo, F. S., Gulletta, E., Rizzo, A., Moretta, A., Karre, K. & 3 others, Ascierto, P. A., Todaro, M. & Carbone, E., May 2019, In : Cancer immunology research. 7, 5, p. 841-852 12 p.

Research output: Contribution to journalArticle

Natural Killer Cells
Melanoma
Galectins
Neoplastic Stem Cells
T-Lymphocyte Subsets
1 Citation (Scopus)

Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial

Eggermont, A. M. M., Chiarion-Sileni, V., Grob, J. J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., Lebbe, C., Ferraresi, V., Smylie, M., Weber, J. S., Maio, M., Hosein, F., de Pril, V., Kicinski, M., Suciu, S. & Testori, A., Sep 1 2019, In : European Journal of Cancer. 119, p. 1-10 10 p.

Research output: Contribution to journalArticle

Melanoma
Placebos
Survival
Neoplasm Metastasis
Recurrence

Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management

Gogas, H. J., Flaherty, K. T., Dummer, R., Ascierto, P. A., Arance, A., Mandala, M., Liszkay, G., Garbe, C., Schadendorf, D., Krajsova, I., Gutzmer, R., Sileni, V. C., Dutriaux, C., de Groot, J. W. B., Yamazaki, N., Loquai, C., Gollerkeri, A., Pickard, M. D. & Robert, C., Sep 1 2019, In : European Journal of Cancer. 119, p. 97-106 10 p.

Research output: Contribution to journalArticle

Open Access
Cohort Studies
Mitogen-Activated Protein Kinase Kinases
Melanoma
encorafenib
MEK162
10 Citations (Scopus)

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable

Cortellini, A., Bersanelli, M., Buti, S., Cannita, K., Santini, D., Perrone, F., Giusti, R., Tiseo, M., Michiara, M., Di Marino, P., Tinari, N., De Tursi, M., Zoratto, F., Veltri, E., Marconcini, R., Malorgio, F., Russano, M., Anesi, C., Zeppola, T., Filetti, M. & 25 others, Marchetti, P., Botticelli, A., Antonini Cappellini, G. C., De Galitiis, F., Vitale, M. G., Rastelli, F., Pergolesi, F., Berardi, R., Rinaldi, S., Tudini, M., Silva, R. R., Pireddu, A., Atzori, F., Chiari, R., Ricciuti, B., De Giglio, A., Iacono, D., Gelibter, A., Occhipinti, M. A., Parisi, A., Porzio, G., Fargnoli, M. C., Ascierto, P. A., Ficorella, C. & Natoli, C., Feb 27 2019, In : Journal for ImmunoTherapy of Cancer. 7, 1, 57.

Research output: Contribution to journalArticle

Open Access
Multicenter Studies
Body Mass Index
Neoplasms
Thinness
Renal Cell Carcinoma

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma

Larkin, J., Brown, M. P., Arance, A. M., Hauschild, A., Queirolo, P., Vecchio, M. D., Ascierto, P. A., Krajsová, I., Schachter, J., Neyns, B., Garbe, C., Sileni, V. C., Mandalà, M., Gogas, H., Espinosa, E., Hospers, G., Lorigan, P., Nyakas, M., Guminski, A., Liszkay, G. & 5 others, Rutkowski, P., Miller, W., Donica, M., Makrutzki, M. & Blank, C., Jan 2019, In : European Journal of Cancer. 107, p. 175-185 11 p.

Research output: Contribution to journalArticle

Multicenter Studies
Melanoma
Safety
Mutation
PLX4032
2 Citations (Scopus)

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system

Larkin, J., Brown, M. P., Arance, A. M., Hauschild, A., Queirolo, P., Vecchio, M. D., Ascierto, P. A., Krajsová, I., Schachter, J., Neyns, B., Garbe, C., Sileni, V. C., Mandalà, M., Gogas, H., Espinosa, E., Hospers, G., Lorigan, P., Nyakas, M., Guminski, A., Liszkay, G. & 5 others, Rutkowski, P., Miller, W., Donica, M., Makrutzki, M. & Blank, C., Jan 1 2019, In : European Journal of Cancer. 107, p. 175-185 11 p.

Research output: Contribution to journalArticle

Multicenter Studies
Melanoma
Safety
Mutation
PLX4032

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system

Larkin, J., Brown, M. P., Arance, A. M., Hauschild, A., Queirolo, P., Vecchio, M. D., Ascierto, P. A., Krajsová, I., Schachter, J., Neyns, B., Garbe, C., Sileni, V. C., Mandalà, M., Gogas, H., Espinosa, E., Hospers, G., Lorigan, P., Nyakas, M., Guminski, A., Liszkay, G. & 5 others, Rutkowski, P., Miller, W., Donica, M., Makrutzki, M. & Blank, C., Jan 2019, In : European Journal of Cancer. 107, p. 175-185 11 p.

Research output: Contribution to journalArticle

Multicenter Studies
Melanoma
Safety
Mutation
PLX4032

A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients

Weide, B., Eigentler, T., Catania, C., Ascierto, P. A., Cascinu, S., Becker, J. C., Hauschild, A., Romanini, A., Danielli, R., Dummer, R., Trefzer, U., Elia, G., Neri, D. & Garbe, C., 2019, In : Cancer Immunology, Immunotherapy.

Research output: Contribution to journalArticle

Dacarbazine
Melanoma
Interleukin-2
Phase II Clinical Trials
Fibronectins

Automatic discovery of image-based signatures for ipilimumab response prediction in malignant melanoma

Harder, N., Schönmeyer, R., Nekolla, K., Meier, A., Brieu, N., Vanegas, C., Madonna, G., Capone, M., Botti, G., Ascierto, P. A. & Schmidt, G., Dec 1 2019, In : Scientific Reports. 9, 1, 7449.

Research output: Contribution to journalArticle

Open Access
Routine Diagnostic Tests
Melanoma
Tumor-Infiltrating Lymphocytes
Decision Trees
Precision Medicine
1 Citation (Scopus)

Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma

Van Herpen, C. M. L., Agarwala, S. S., Hauschild, A., Berking, C., Thaddeus Beck, J., Schadendorf, D., Jansen, R., Queirolo, P., Ascierto, P. A., Blank, C. U., Heinrich, M. C., Pal, R. R., Derti, A., Antona, V., Nauwelaerts, H., Zubel, A. & Dummer, R., Mar 1 2019, In : Oncotarget. 10, 19, p. 1850-1859 10 p.

Research output: Contribution to journalArticle

Melanoma
Biomarkers
Mitogen-Activated Protein Kinases
Mitogen-Activated Protein Kinase Kinases
Mutation

BRAF Mutations and Dysregulation of the MAP Kinase Pathway Associated to Sinonasal Mucosal Melanomas

Colombino, M., Paliogiannis, P., Cossu, A., De Re, V., Miolo, G., Botti, G., Scognamiglio, G., Ascierto, P. A., Santeufemia, D. A., Fraggetta, F., Manca, A., Sini, M. C., Casula, M., Palomba, G., Pisano, M., Doneddu, V., Lissia, A., Fedeli, M. A. & Palmieri, G., Oct 1 2019, In : Journal of Clinical Medicine. 8, 10

Research output: Contribution to journalArticle

Melanoma
Phosphotransferases
Mutation
Genes
Immune Tolerance

Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab

Quagliariello, V., Passariello, M., Coppola, C., Rea, D., Barbieri, A., Scherillo, M., Monti, M. G., Iaffaioli, R. V., De Laurentiis, M., Ascierto, P. A., Botti, G., De Lorenzo, C. & Maurea, N., 2019, In : International Journal of Cardiology.

Research output: Contribution to journalArticle

NF-kappa B
Leukotriene B4
Cardiac Myocytes
Interleukins
Immunotherapy
4 Citations (Scopus)

Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC

Antonia, S. J., Balmanoukian, A., Brahmer, J., Ou, S. H. I., Hellmann, M. D., Kim, S. W., Ahn, M. J., Kim, D. W., Gutierrez, M., Liu, S. V., Schöffski, P., Jäger, D., Jamal, R., Jerusalem, G., Lutzky, J., Nemunaitis, J., Calabrò, L., Weiss, J., Gadgeel, S., Bhosle, J. & 11 others, Ascierto, P. A., Rebelatto, M. C., Narwal, R., Liang, M., Xiao, F., Antal, J., Abdullah, S., Angra, N., Gupta, A. K., Khleif, S. N. & Segal, N. H., Oct 1 2019, In : Journal of Thoracic Oncology. 14, 10, p. 1794-1806 13 p.

Research output: Contribution to journalArticle

Open Access
Cell Death
Ligands
Safety
Disease-Free Survival
Pneumonia
4 Citations (Scopus)

Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study

Cortellini, A., Buti, S., Santini, D., Perrone, F., Giusti, R., Tiseo, M., Bersanelli, M., Michiara, M., Grassadonia, A., Brocco, D., Tinari, N., De Tursi, M., Zoratto, F., Veltri, E., Marconcini, R., Malorgio, F., Garufi, C., Russano, M., Anesi, C., Zeppola, T. & 25 others, Filetti, M., Marchetti, P., Botticelli, A., Antonini Cappellini, G. C., De Galitiis, F., Vitale, M. G., Sabbatini, R., Bracarda, S., Berardi, R., Rinaldi, S., Tudini, M., Silva, R. R., Pireddu, A., Atzori, F., Chiari, R., Ricciuti, B., Iacono, D., Migliorino, M. R., Rossi, A., Porzio, G., Cannita, K., Ciciarelli, V., Fargnoli, M. C., Ascierto, P. A. & Ficorella, C., 2019, In : Oncologist.

Research output: Contribution to journalArticle

Preexisting Condition Coverage
Immunotherapy
Autoimmune Diseases
Neoplasms
Incidence
Biological Factors
Antineoplastic Agents
clinical trials
Clinical Trials
Costs and Cost Analysis

Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: An insight from clinical practice

Cortellini, A., Vitale, M. G., De Galitiis, F., Di Pietro, F. R., Berardi, R., Torniai, M., De Tursi, M., Grassadonia, A., Di Marino, P., Santini, D., Zeppola, T., Anesi, C., Gelibter, A., Occhipinti, M. A., Botticelli, A., Marchetti, P., Rastelli, F., Pergolesi, F., Tudini, M., Silva, R. R. & 5 others, Mallardo, D., Vanella, V., Ficorella, C., Porzio, G. & Ascierto, P. A., Nov 15 2019, In : Journal of Translational Medicine. 17, 1, 376.

Research output: Contribution to journalArticle

Corrosion inhibitors
Fatigue
Fatigue of materials
Neoplasms
Renal Cell Carcinoma
1 Citation (Scopus)

Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAFV600 mutation–positive metastatic melanoma treated with vemurafenib ± cobimetinib

Lewis, K., Hauschild, A., Larkin, J., Ribas, A., Flaherty, K. T., McArthur, G. A., Dréno, B., McKenna, E., Zhu, Q., Mun, Y. & Ascierto, P. A., Jul 1 2019, In : European Journal of Cancer. 116, p. 45-55 11 p.

Research output: Contribution to journalArticle

Reducing Agents
Melanoma
Acids
Survival
GDC-0973

ErbB3 Phosphorylation as Central Event in Adaptive Resistance to Targeted Therapy in Metastatic Melanoma: Early Detection in CTCs during Therapy and Insights into Regulation by Autocrine Neuregulin

Ruggiero, C. F., Malpicci, D., Fattore, L., Madonna, G., Vanella, V., Mallardo, D., Liguoro, D., Salvati, V., Capone, M., Bedogni, B., Ascierto, P. A., Mancini, R. & Ciliberto, G., Sep 25 2019, In : Cancers. 11, 10

Research output: Contribution to journalArticle

Neuregulins
Circulating Neoplastic Cells
Cell- and Tissue-Based Therapy
Melanoma
Phosphorylation

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial

Lebbé, C., Meyer, N., Mortier, L., Marquez-Rodas, I., Robert, C., Rutkowski, P., Menzies, A. M., Eigentler, T., Ascierto, P. A., Smylie, M., Schadendorf, D., Ajaz, M., Svane, I. M., Gonzalez, R., Rollin, L., Lord-Bessen, J., Saci, A., Grigoryeva, E. & Pigozzo, J., Apr 10 2019, In : Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 37, 11, p. 867-875 9 p.

Research output: Contribution to journalArticle

Melanoma
Disease-Free Survival
Incidence
Survival
Therapeutics
3 Citations (Scopus)

First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis

Schilling, B., Martens, A., Geukes Foppen, M. H., Gebhardt, C., Hassel, J. C., Rozeman, E. A., Gesierich, A., Gutzmer, R., Kähler, K. C., Livingstone, E., Diamantopoulos, P. T., Gogas, H., Madonna, G., Ascierto, P. A., Goldinger, S. M., Mangana, J., Garbe, C., Schadendorf, D., Blank, C. & Weide, B., Jan 1 2019, In : Cancer Immunology, Immunotherapy.

Research output: Contribution to journalArticle

Melanoma
Death Domain Receptors
Survival
Mitogen-Activated Protein Kinases
Therapeutics

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J-J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., Ferrucci, P. F., Smylie, M., Hogg, D., Hill, A., Márquez-Rodas, I., Haanen, J., Guidoboni, M., Maio, M., Schöffski, P., Carlino, M. S. & 11 others, Lebbé, C., McArthur, G., Ascierto, P. A., Daniels, G. A., Long, G. V., Bastholt, L., Rizzo, J. I., Balogh, A., Moshyk, A., Hodi, F. S. & Wolchok, J. D., Oct 17 2019, In : The New England journal of medicine. 381, 16, p. 1535-1546 12 p.

Research output: Contribution to journalArticle

Melanoma
Survival
ipilimumab
nivolumab
Disease-Free Survival

Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAFV600-mutated Metastatic Melanoma

Yan, Y., Wongchenko, M. J., Robert, C., Larkin, J., Ascierto, P. A., Dréno, B., Maio, M., Garbe, C., Chapman, P. B., Sosman, J. A., Shi, Z., Koeppen, H., Hsu, J. J., Chang, I., Caro, I., Rooney, I., McArthur, G. A. & Ribas, A., 2019, In : Clinical Cancer Research.

Research output: Contribution to journalArticle

Melanoma
Exome
Neoplasms
Programmed Cell Death 1 Receptor
Genes
2 Citations (Scopus)

Germline and somatic mutations in patients with multiple primary melanomas: A next generation sequencing study

Casula, M., Paliogiannis, P., Ayala, F., De Giorgi, V., Stanganelli, I., Mandalà, M., Colombino, M., Manca, A., Sini, M. C., Caracò, C., Ascierto, P. A., Satta, R. R., Dedola, M. F., Denti, S., Fedeli, M. A., Montesu, M. A., Profili, S., Scotto, T., Sini, G., Tanda, F. & 9 others, Lissia, A., Cossu, A., Palmieri, G., Ghiorzo, P., Queirolo, P., Quaglino, P., Botti, G., Sileni, V. C. & Di Giacomo, A. M., Aug 5 2019, In : BMC Cancer. 19, 1, 772.

Research output: Contribution to journalArticle

Open Access
Germ-Line Mutation
Melanoma
Mutation
Italy
Population

Health-related quality of life in patients with fully resected BRAFV600 mutation–positive melanoma receiving adjuvant vemurafenib

the BRIM8 Investigators, Dec 2019, In : European Journal of Cancer. 123, p. 155-161 7 p.

Research output: Contribution to journalArticle

Melanoma
Quality of Life
Health Status
Therapeutics
PLX4032

Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM

Lewis, K. D., Larkin, J., Ribas, A., Flaherty, K. T., McArthur, G. A., Ascierto, P. A., Dréno, B., Yan, Y., Wongchenko, M., McKenna, E., Zhu, Q., Mun, Y. & Hauschild, A., Jan 1 2019, In : British Journal of Cancer.

Research output: Contribution to journalArticle

Open Access
Survival
Disease-Free Survival
Melanoma
Genes
GDC-0973

Mutational concordance between primary and metastatic melanoma: A next-generation sequencing approach

Manca, A., Paliogiannis, P., Colombino, M., Casula, M., Lissia, A., Botti, G., Caracò, C., Ascierto, P. A., Sini, M. C., Palomba, G., Pisano, M., Dedola, M. F., Fedeli, M. A., Montesu, M. A., Rubino, C., Satta, R., Scotto, T., Sini, G., Maio, M., Massi, D. & 10 others, Anichini, A., Pfeffer, U., Doneddu, V., Cossu, A., Palmieri, G., Ghiorzo, P., Queirolo, P., Quaglino, P., Sileni, V. C. & Di Giacomo, A. M., Aug 28 2019, In : Journal of Translational Medicine. 17, 1, 289.

Research output: Contribution to journalArticle

Open Access
Melanoma
Genes
Tissue
Mutation
Literature

Mutational concordance between primary and metastatic melanoma: A next-generation sequencing approach

Manca, A., Paliogiannis, P., Colombino, M., Casula, M., Lissia, A., Botti, G., Caracò, C., Ascierto, P. A., Sini, M. C., Palomba, G., Pisano, M., Dedola, M. F., Fedeli, M. A., Montesu, M. A., Rubino, C., Satta, R., Scotto, T., Sini, G., Maio, M., Massi, D. & 10 others, Anichini, A., Pfeffer, U., Doneddu, V., Cossu, A., Palmieri, G., Ghiorzo, P., Queirolo, P., Quaglino, P., Sileni, V. C. & Di Giacomo, A. M., 2019, In : Journal of Translational Medicine. 17, 1

Research output: Contribution to journalArticle

Melanoma
Genes
Tissue
Mutation
Literature

Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results

Sharma, P., Siefker-Radtke, A., de Braud, F., Basso, U., Calvo, E., Bono, P., Morse, M. A., Ascierto, P. A., Lopez-Martin, J., Brossart, P., Rohrberg, K., Mellado, B., Fischer, B. S., Meadows-Shropshire, S., Abdel Saci, Callahan, M. K. & Rosenberg, J., 2019, In : Journal of clinical oncology : official journal of the American Society of Clinical Oncology. p. JCO1900538

Research output: Contribution to journalArticle

Carcinoma
Platinum
Immunotherapy
Multicenter Studies
Disease Progression

Nivolumab for the treatment of small cell lung cancer

Simeone, E., Grimaldi, A. M., Festino, L., Trojaniello, C., Vitale, M. G., Vanella, V., Curvietto, M. & Ascierto, P. A., Jan 1 2019, (Accepted/In press) In : Expert Review of Respiratory Medicine.

Research output: Contribution to journalArticle

Small Cell Lung Carcinoma
Drug Therapy
Immunotherapy
Clinical Trials
Therapeutics

Perspectives in melanoma: Meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy)

Ascierto, P. A., Agarwala, S. S., Botti, G., Budillon, A., Davies, M. A., Dummer, R., Ernstoff, M., Ferrone, S., Formenti, S., Gajewski, T. F., Garbe, C., Hamid, O., Lo, R. S., Luke, J. J., Michielin, O., Palmieri, G., Zitvogel, L., Marincola, F. M., Masucci, G., Caracò, C. & 2 others, Thurin, M. & Puzanov, I., Jul 22 2019, In : Journal of Translational Medicine. 17, 1, 234.

Research output: Contribution to journalArticle

Open Access
Italy
Tumors
Melanoma
Biomarkers
Neoplasms
7 Citations (Scopus)

Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma

Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V. G., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., Sandhu, S., Larkin, J., Puig, S., Ascierto, P. A., Rutkowski, P., Schadendorf, D., Koornstra, R., Hernandez-Aya, L., Di Giacomo, A. M., van den Eertwegh, A. JM. & 12 others, Grob, J. J., Gutzmer, R., Jamal, R., Lorigan, P. C., Lupinacci, R., Krepler, C., Ibrahim, N., Kicinski, M., Marreaud, S., van Akkooi, A. C., Suciu, S. & Robert, C., Jul 1 2019, In : European Journal of Cancer. 116, p. 148-157 10 p.

Research output: Contribution to journalArticle

Melanoma
Placebos
Recurrence
Neoplasms
Survival
5 Citations (Scopus)

Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations

Ascierto, P. A., Capone, M., Grimaldi, A. M., Mallardo, D., Simeone, E., Madonna, G., Roder, H., Meyer, K., Asmellash, S., Oliveira, C., Roder, J. & Grigorieva, J., Mar 29 2019, In : Journal for ImmunoTherapy of Cancer. 7, 1, 91.

Research output: Contribution to journalArticle

Proteomics
Melanoma
Mutation
Disease-Free Survival
Survival

Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma

Fattore, L., Ruggiero, C. F., Pisanu, M. E., Liguoro, D., Cerri, A., Costantini, S., Capone, F., Acunzo, M., Romano, G., Nigita, G., Mallardo, D., Ragone, C., Carriero, M. V., Budillon, A., Botti, G., Ascierto, P. A., Mancini, R. & Ciliberto, G., Jul 2019, In : Cell Death and Differentiation. 26, 7, p. 1267-1282 16 p.

Research output: Contribution to journalArticle

MicroRNAs
Drug Resistance
Melanoma
Recurrence
Mitogen-Activated Protein Kinase Kinases
1 Citation (Scopus)

Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)

Nathan, P., Ascierto, P. A., Haanen, J., Espinosa, E., Demidov, L., Garbe, C., Guida, M., Lorigan, P., Chiarion-Sileni, V., Gogas, H., Maio, M., Fierro, M. T., Hoeller, C., Terheyden, P., Gutzmer, R., Guren, T. K., Bafaloukos, D., Rutkowski, P., Plummer, R., Waterston, A. & 8 others, Kaatz, M., Mandala, M., Marquez-Rodas, I., Muñoz-Couselo, E., Dummer, R., Grigoryeva, E., Young, T. C. & Schadendorf, D., Sep 1 2019, In : European Journal of Cancer. 119, p. 168-178 11 p.

Research output: Contribution to journalArticle

Melanoma
Safety
Therapeutics
Skin
ipilimumab

Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab

(IMI), O. B. O. T. I. M. I., Pistillo, M. P., Fontana, V., Morabito, A., Dozin, B., Laurent, S., Carosio, R., Banelli, B., Ferrero, F., Spano, L., Tanda, E., Ferrucci, P. F., Martinoli, C., Cocorocchio, E., Guida, M., Tommasi, S., De Galitiis, F., Pagani, E., Antonini Cappellini, G. C., Marchetti, P. & 9 others, Quaglino, P., Fava, P., Osella-Abate, S., Ascierto, P. A., Capone, M., Simeone, E., Romani, M., Spagnolo, F. & Queirolo, P., 2019, In : Cancer Immunology and Immunotherapy.

Research output: Contribution to journalArticle

Melanoma
Biomarkers
ipilimumab
Survival Analysis
Serum

Survival Outcomes in Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma Treated with Nivolumab Therapy

Ascierto, P. A., Long, G. V., Robert, C., Brady, B., Dutriaux, C., Di Giacomo, A. M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., Savage, K. J., Hernberg, M. M., Lebbé, C., Charles, J., Mihalcioiu, C., Chiarion-Sileni, V., Mauch, C., Cognetti, F., Ny, L. & 8 others, Arance, A., Svane, I. M., Schadendorf, D., Gogas, H., Saci, A., Jiang, J., Rizzo, J. & Atkinson, V., 2019, In : JAMA oncology.

Research output: Contribution to journalArticle

Dacarbazine
Melanoma
Survival
Programmed Cell Death 1 Receptor
Age Groups

Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade

Jacquelot, N., Yamazaki, T., Roberti, M. P., Duong, C. P. M., Andrews, M. C., Verlingue, L., Ferrere, G., Becharef, S., Vétizou, M., Daillère, R., Messaoudene, M., Enot, D. P., Stoll, G., Ugel, S., Marigo, I., Foong Ngiow, S., Marabelle, A., Prevost-Blondel, A., Gaudreau, P. O., Gopalakrishnan, V. & 13 others, Eggermont, A. M., Opolon, P., Klein, C., Madonna, G., Ascierto, P. A., Sucker, A., Schadendorf, D., Smyth, M. J., Soria, J. C., Kroemer, G., Bronte, V., Wargo, J. & Zitvogel, L., 2019, In : Cell Research.

Research output: Contribution to journalArticle

Interferon Type I
Regulatory T-Lymphocytes
Nitric Oxide Synthase
Monoclonal Antibodies
Immunotherapy

The great debate at "melanoma Bridge 2018", Naples, December 1st, 2018

Ascierto, P. A., Bruzzi, P., Eggermont, A., Hamid, O., Tawbi, H. A., Van Akkooi, A., Testori, A., Caracò, C., Puzanov, I. & Perrone, F., May 10 2019, In : Journal of Translational Medicine. 17, 1, 148.

Research output: Contribution to journalArticle

Open Access
CTLA-4 Antigen
Melanoma
Ligands
Pharmaceutical Preparations
Neoadjuvant Therapy
2 Citations (Scopus)

The potential of BRAF-associated non-coding RNA as a therapeutic target in melanoma

Fattore, L., Mancini, R., Ascierto, P. A. & Ciliberto, G., Jan 2 2019, In : Expert Opinion on Therapeutic Targets. 23, 1, p. 53-68 16 p.

Research output: Contribution to journalArticle

Untranslated RNA
Melanoma
Deregulation
Expert Testimony
Therapeutics
2018
249 Citations (Scopus)

Adjuvant pembrolizumab versus placebo in resected stage III melanoma

Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., Sandhu, S., Larkin, J., Puig, S., Ascierto, P. A., Rutkowski, P., Schadendorf, D., Koornstra, R., Hernandez-Aya, L., Maio, M., Van Den Eertwegh, A. J. M. & 9 others, Grob, J. J., Gutzmer, R., Jamal, R., Lorigan, P., Ibrahim, N., Marreaud, S., Van Akkooi, A. C. J., Suciu, S. & Robert, C., May 10 2018, In : New England Journal of Medicine. 378, 19, p. 1789-1801 13 p.

Research output: Contribution to journalArticle

Melanoma
Placebos
Recurrence
Survival
Poisons
35 Citations (Scopus)

Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

Maio, M., Lewis, K., Demidov, L., Mandalà, M., Bondarenko, I., Ascierto, P., Herbert, C., Mackiewicz, A., Rutkowski, P., Guminski, A., Goodman, G. R., Simmons, B., Ye, C., Yan, Y., Schadendorf, D., Cinat, G., Fein, L. E., Brown, M., Guminski, A., Haydon, A. & 24 others, Khattak, A., McNeil, C., Parente, P., Power, J., Roberts-Thomson, R., Sandhu, S., Underhill, C., Varma, S., Berger, T., Awada, A., Blockx, N., Buyse, V., Mebis, J., Franke, F. A., Jobim de Azevedo, S., Silva Lazaretti, N., Jamal, R., Mihalcioiu, C., Petrella, T., Savage, K., Bianchi, L., Chiarion Sileni, V., Cognetti, F. & Gianni, L., Apr 1 2018, In : The Lancet Oncology. 19, 4, p. 510-520 11 p.

Research output: Contribution to journalArticle

Melanoma
Placebos
Mutation
Disease-Free Survival
Keratoacanthoma
17 Citations (Scopus)

Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection

Tio, M., Rai, R., Ezeoke, O. M., McQuade, J. L., Zimmer, L., Khoo, C., Park, J. J., Spain, L., Turajlic, S., Ardolino, L., Yip, D., Goldinger, S. M., Cohen, J. V., Millward, M., Atkinson, V., Kane, A. Y., Ascierto, P. A., Garbe, C., Gutzmer, R., Johnson, D. B. & 5 others, Rizvi, H. A., Joshua, A. M., Hellmann, M. D., Long, G. V. & Menzies, A. M., Nov 1 2018, In : European Journal of Cancer. 104, p. 137-144 8 p.

Research output: Contribution to journalArticle

Hepatitis C
Hepatitis B
Immunotherapy
HIV
Transplants
20 Citations (Scopus)

A serum protein signature associated with outcome after anti-PD-1 therapy in metastatic melanoma

Weber, J. S., Sznol, M., Sullivan, R. J., Blackmon, S., Boland, G., Kluger, H. M., Halaban, R., Bacchiocchi, A., Ascierto, P. A., Capone, M., Oliveira, C., Meyer, K., Grigorieva, J., Asmellash, S. G., Roder, J. & Roder, H., Jan 1 2018, In : Cancer immunology research. 6, 1, p. 79-86 8 p.

Research output: Contribution to journalArticle

Blood Proteins
Melanoma
Mass Spectrometry
Therapeutics
Acute-Phase Proteins

Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study

Hansson, J., Bartley, K., Karagiannis, T., Grob, J-J., Kunstfeld, R., Dréno, B., Mortier, L., Ascierto, P. A., Licitra, L., Dutriaux, C., Thomas, L., Meyer, N., Guillot, B., Dummer, R., Fife, K., Ernst, D. S., Yim, Y. M., Dimier, N., Fittipaldo, A., Basset-Séguin, N. & 1 others, Hauschild, A., Dec 1 2018, In : European journal of dermatology : EJD. 28, 6, p. 775-783 9 p.

Research output: Contribution to journalArticle

HhAntag691
Basal Cell Carcinoma
Quality of Life
Equipment and Supplies
Patient Safety

Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib

Wongchenko, M. J., Ribas, A., Dréno, B., Ascierto, P. A., McArthur, G. A., Gallo, J. D., Rooney, I. A., Hsu, J., Koeppen, H., Yan, Y. & Larkin, J., Jul 2018, In : Pigment Cell and Melanoma Research. 31, 4, p. 516-522 7 p.

Research output: Contribution to journalArticle

Melanoma
Ligands
Mutation
Disease-Free Survival
Survival
Melanoma
Neutrophils
Lymphocytes
Survival
Disease-Free Survival
57 Citations (Scopus)

CheckMate-032 study: Efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer

Janjigian, Y. Y., Bendell, J., Calvo, E., Kim, J. W., Ascierto, P. A., Sharma, P., Ott, P. A., Peltola, K., Jaeger, D., Evans, J., De Braud, F., Chau, I., Harbison, C. T., Dorange, C., Tschaika, M. & Le, D. T., Oct 1 2018, In : Journal of Clinical Oncology. 36, 28, p. 2836-2844 9 p.

Research output: Contribution to journalArticle

Safety
Neoplasms
Drug Therapy
Esophagogastric Junction
Survival

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer

Janjigian, Y. Y., Bendell, J., Calvo, E., Kim, J. W., Ascierto, P. A., Sharma, P., Ott, P. A., Peltola, K., Jaeger, D., Evans, J., de Braud, F., Chau, I., Harbison, C. T., Dorange, C., Tschaika, M. & Le, D. T., Oct 1 2018, In : Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 36, 28, p. 2836-2844 9 p.

Research output: Contribution to journalArticle

Safety
Neoplasms
Drug Therapy
Esophagogastric Junction
Survival

CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab

(IMI), I. M. I., Queirolo, P., Dozin, B., Morabito, A., Banelli, B., Carosio, R., Fontana, V., Ferrucci, P. F., Martinoli, C., Cocorocchio, E., Ascierto, P. A., Madonna, G., Simeone, E., De Galitiis, F., Antonini Cappellini, G. C., Marchetti, P., Guida, M., Tommasi, S., Ghilardi, L., Merelli, B. & 7 others, Fava, P., Osella-Abate, S., Guidoboni, M., Romani, M., Ferone, D., Spagnolo, F. & Pistillo, M. P., Jul 1 2018, In : European Journal of Cancer. 97, p. 59-61 3 p.

Research output: Contribution to journalArticle

CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab

Queirolo, P., Dozin, B., Morabito, A., Banelli, B., Carosio, R., Fontana, V., Ferrucci, P. F., Martinoli, C., Cocorocchio, E., Ascierto, P. A., Madonna, G., Simeone, E., De Galitiis, F., Antonini Cappellini, G. C., Marchetti, P., Guida, M., Tommasi, S., Ghilardi, L., Merelli, B., Fava, P. & 7 others, Osella-Abate, S., Guidoboni, M., Romani, M., Ferone, D., Spagnolo, F., Pistillo, M. P. & (IMI), I. M. I., 2018, In : European journal of cancer. 97, p. 59-61 3 p.

Research output: Contribution to journalArticle